Thermo Fisher Scientific (TMO) spends approximately $700 million on R&D (research and development) per year sporting the largest R&D budget in the laboratory equipment industry as compared to its peers. The company now has more than 800,000 products in its portfolio with an extensive product pipeline and also has a leading patent portfolio. Thermo has since established itself as a leading player in biosciences and offers a comprehensive portfolio of products to fulfill customer needs. The company is also a leader in targeted genomics applications.
Thermo Fisher Scientific has a presence in more than 50 countries. The company has established a strong presence in China through various strategies and partnerships and through a localized approach to business. The lucrative Chinese market is huge for Thermo Fisher and the company expects China to impact growth significantly going forward as it is the company’s second-largest market. The company now aims to replicate its China strategies in other emerging markets like India, Korea, and Singapore.
The aging population and growth in emerging markets represent strong long-term opportunities for Thermo Fisher Scientific in biomedical research, diagnostics markets, environmental and applied markets.
Thermo Fisher Scientific is well positioned for long-term growth due to its leading market position and strong product portfolio. Strength in the biopharma market is also estimated to drive the company’s revenues and profitability. The growing demand of biologics and vaccine development is creating short-term as well as long-term opportunities for the company.
Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Thermo Fisher Scientific operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Through the Life Sciences Solutions segment, it provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of disease. Through the Analytical Instruments segment, it provides instruments, consumables, software and services. The Specialty Diagnostics segment offers diagnostic test kits, reagents, culture media, instruments and associated products. The Laboratory Products and Services segment offers self-manufactured and sourced products for the laboratory.
TMO stock has been a great performer over the last few years specifically since 2013. Currently the stock is peaking at the top of a short-term uptrend channel with support coming in at the $145 level. Long-term support is $120. If $120 were to give way, that could prove deadly for the stock on a technical basis.
Drug Stock News 